Summary
Global Markets Direct’s, ‘Emergent BioSolutions Inc. - Product Pipeline Review - 2016’, provides an overview of the Emergent BioSolutions Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Emergent BioSolutions Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Emergent BioSolutions Inc.
- The report provides overview of Emergent BioSolutions Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Emergent BioSolutions Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Emergent BioSolutions Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Emergent BioSolutions Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Emergent BioSolutions Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Emergent BioSolutions Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Emergent BioSolutions Inc. Snapshot 6
Emergent BioSolutions Inc. Overview 6
Key Information 6
Key Facts 6
Emergent BioSolutions Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Emergent BioSolutions Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Emergent BioSolutions Inc. - Pipeline Products Glance 14
Emergent BioSolutions Inc. - Late Stage Pipeline Products 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Emergent BioSolutions Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Emergent BioSolutions Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Emergent BioSolutions Inc. - Drug Profiles 19
coagulation factor IX (recombinant) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AV-7909 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
otlertuzumab 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PreviThrax 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ES-414 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
5-E3 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
antihemophilic factor (recombinant) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ES-210 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ES-301 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ES-306 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EV-035 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GC-072 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MVA-RSV 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MVAH-5HA 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein to Inhibit CD19 and CD3 for B-Cell Lymphoma 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MonoClonal Antibody for Ebola and Marburg Infections 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Recombinant Protein to Target HER-2 and CD3 for Cancer 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Recombinant Protein to Target RON and CD3 for Cancer 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccines for Undisclosed Indication 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Emergent BioSolutions Inc. - Pipeline Analysis 42
Emergent BioSolutions Inc. - Pipeline Products by Target 42
Emergent BioSolutions Inc. - Pipeline Products by Route of Administration 44
Emergent BioSolutions Inc. - Pipeline Products by Molecule Type 45
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action 46
Emergent BioSolutions Inc. - Recent Pipeline Updates 48
Emergent BioSolutions Inc. - Dormant Projects 57
Emergent BioSolutions Inc. - Dormant Projects 57
Emergent BioSolutions Inc. - Discontinued Pipeline Products 58
Discontinued Pipeline Product Profiles 58
Anthrivig 58
Immune Globulin 58
Leucotropin 58
PEP-35 58
TST-10088 58
Emergent BioSolutions Inc. - Company Statement 59
Emergent BioSolutions Inc. - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68
List of Tables
Emergent BioSolutions Inc., Key Information 6
Emergent BioSolutions Inc., Key Facts 6
Emergent BioSolutions Inc. - Pipeline by Indication, 2016 8
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2016 10
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2016 11
Emergent BioSolutions Inc. - Partnered Products in Pipeline, 2016 12
Emergent BioSolutions Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13
Emergent BioSolutions Inc. - Filing rejected/Withdrawn, 2016 14
Emergent BioSolutions Inc. - Phase II, 2016 15
Emergent BioSolutions Inc. - Phase I, 2016 16
Emergent BioSolutions Inc. - Preclinical, 2016 17
Emergent BioSolutions Inc. - Discovery, 2016 18
Emergent BioSolutions Inc. - Pipeline by Target, 2016 42
Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2016 44
Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2016 45
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action, 2016 46
Emergent BioSolutions Inc. - Recent Pipeline Updates, 2016 48
Emergent BioSolutions Inc. - Dormant Developmental Projects,2016 57
Emergent BioSolutions Inc. - Discontinued Pipeline Products, 2016 58
Emergent BioSolutions Inc., Other Locations 64
Emergent BioSolutions Inc., Subsidiaries 64
List of Figures
Emergent BioSolutions Inc. - Pipeline by Top 10 Indication, 2016 8
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2016 10
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2016 11
Emergent BioSolutions Inc. - Pipeline by Top 10 Target, 2016 42
Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2016 44
Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2016 45
Emergent BioSolutions Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 46
